台灣基因醫學暨生物標記學會

最新消息	>首頁>最新消息>【公告】2019多體學及精準醫學聯合會議海報展演名單與口頭報告名單

【公告】2019多體學及精準醫學聯合會議海報展演名單與口頭報告名單

本公告附加檔案:

2019/11/29

2019多體學及精準醫學聯合會議

詳情請見大會官網

口頭報告名單:
※每位講員依報告順序依序進行口頭報告，時間各13分鐘(10分鐘口頭報告，3分鐘發問問題)

OC-01	王庭	Combination Therapy with Dendritic Cell Vaccine and PD-L1 Immune Checkpoint Inhibitor for Hepatocellular Carcinoma in An Orthotopic Mouse Model
OC-02	翁靖傑	Loss of the Transcriptional Repressor TGIF1 Results in Enhanced Kras-Driven Development of Pancreatic Cancer
OC-03	石一㚬	A Turn-on Fluorescence Sensor for Heparin Detection Based on a Release of Taiwan Cobra Cardiotoxin from a DNA Aptamer or Adenosine-Based Molecular Beacon
OC-04	鄭以安	Non-covalent modification of mPEGylated nanoparticles by humanized bispecific antibodies for selective therapy
OC-05	王亮鈞	VINCRISTINE INDUCES APOPTOSIS OF HUMAN LEUKEMIA U937 CELLS VIA SIRT3/ROS/p38 MAPK/TTP AXIS-MEDIATED TNF-α UPREGULATION
OC-06	呂韻綺	Specific activation of a pro-Remicade can enhance the selectivity and safety of rheumatoid arthritis therapy

海報展演名單:

C1-01	黃信凱	Investigation of influence of microbiota on colorectal cancer patients using Irinotecan (CPT-11) induced diarrhea
C2-01	吳怡萱	Development of the protease-activated pro-Humira to prevent the interfere effect of neutralizing anti-idiotype antibody
C2-02	李子瑜	Development of pro-immune checkpoint antibody to increase selectivity and reduce side effects
C2-03	※吳亭儀	Non-covalent Modified mPEGylated Nanodrugs with Anti-PEG Bispecific Antibody(αmPEGxαCD20) to Enhance Tumor Specific Targeting and Therapeutic Efficacy in Lymphoma
C2-04	黃怡嘉	To compare the immunogenicity of pro-antibody that mask antibody-binding sites with hinge domain or coiled-coil domain in mice model
C4-01	劉建均	Screening of DNA aptamers toward oral cancer biomarkers using plate-based SELEX and next-generation sequencing
C4-02	葉宏淳	Butanolide compounds from Cinnamomum kotoense induce melanoma autophagy and apoptosis via MAPK pathway in vivo and in vitro
C4-03	詹雅玲	Human T-cell lymphoma invasion and metastasis 2 promotes chronic inflammation mediated tumorigenicity
C4-04	傅曉婷	The survival time of non-small cell lung cancer patients conducted with different treatments, alone or in combination: A single center study.
C4-05	林宜玫	The relationship of serotonin receptor 1A polymorphisms with woman menopause symptom and pro-inflammatory cytokines
C4-06	張培均	Inhibition Assessment of Anticancer Drugs for ALK Gene Variation Target
C4-07	※王怡絜	O-Methyleugenol from Cinnamomum subavenium Enhance Doxorubicin Chemotherapy Efficacy to Inhibit Human Lung Cancer Cell Proliferation and Reverse Epithelial-to-Mesenchymal Transition Pathway
C4-08	吳秉璁	Development of a humanized bi-specific antibody (αEphA2×α-mPEG) for specific targeting and endocytosis of glycosidic switch liposomes to EphA2-expressing metastatic tumors
C4-09	※黃佳慧	ARSENIC TRIOXIDE INDUCES APOPTOSIS IN BCR-ABL1-POSITIVE LEUKEMIA CELLS VIA P38 MAPK-AND AKT-MEDIATED MCL1 DOWNREGULATION
C4-10	李苑親	EGFR-Mediated AGO2 Phosphorylation Upregulates MCL1 Expression in ABT-263-treated Human Leukemia Cells
C4-11	邱靖婷	AUTOPHAGIC DEGRADATION OF HUR ELICITS DOWNREGULATION OF SURVIVIN AND MCL1 IN YM-155-TREATED HUMAN LEUKEMIA K562 CELLS
C4-12	黃奕中	Tet-on the expression of ERCC1 increase radioresistance of colorectal cancer in vivo
C4-13	萬郁瑩	Extract Capsicum annuum chemical composition and enhance chemodrug inhibition lung cancer growth
C4-14	謝雅茹	The Roles of GSKIP in Metastatic Ability and Radioresistance of Oral Squamous Cell Carcinoma
C4-15	黃柏誠	Development of protease-activated pro-antibody by structure-based computational methods
C4-16	陳慧蓁	An autologous hinge as universal antibody lock enhances selectivity of antibody whilst prevent the binding of anti-idiotype antibody
C4-17	李安倫	The microRNA classifiers as ancillary diagnosis biomarkers for urothelial carcinoma of chronic kidney disease
C4-18	吳佩珊	Development of protease-activated pro-anti-CTLA4 antibody to enhance disease selectivity and reduce the side effects
C4-19	李承恩	To investigate the importance of disulfide bond to spatial-hindrance-based pro-antibody
C4-20	李佳靜	One-step Mixing of Anti-mPEG Bispecific Antibody (mPEG×HER2) with PEGylated Nanoparticles to Enhance Its Therapeutic Efficacy in Ovarian Cancer
C4-21	蔡婉琪	Compound X from Ardisia virens inhibits tumorigenesis and metastatic potential in pancreatic cancer
C4-22	全鄧雅文	Effect of fucoidan from Fucus vesiculosus on lung adenocarcinoma cells resistance to chemotherapeutic drug doxorubicin
C4-23	王碩鴻	To develop a protease inhibitor for Zika virus therapy
C4-24	柯建志	Radiation-modulated prostate cancer derived-exosomes regulates the epithelial-mesenchymal transition of recipient cells
C4-25	廖子毅	Bispecific antibody (CD20 Ab × mPEG scFv) specific targets liquid tumors to enhance anti-tumor efficacy by actively grab PEGylated liposomal doxorubicin
C4-26	※趙郁舒	Leader compounds provide less cytotoxicity and higher specificity to inhibit type I~IV Dengue
C4-27	※陳怡如	Developing Bispecific Antibody for Synergistic Anti-Cancer Effects by Precise Targeting and Accumulation of PEGylated Drugs
C4-28	洪詩婷	Correlation of anti-PEG antibody with the therapeutic efficacy of Mircera
C4-29	劉蕙如	Targeted mPEG-nanoparticle Release into Blood-Brain Barrier by a Protease Cleavable BsAb (mPEG×TfR)

口頭論文，海報發表規則

規則:

每篇至少請一位作者完成報名及註冊繳費程序。
Oral presentation 報告議程及順序請參考「投稿結果公告」頁面。
poster論文議程、海報編號請參考公告。
12/7 13:00~14:00由編號單數號報告；12/8 13:00~14:00由編號雙數號報告。

口頭論文發表規則:

口頭發表時間 : 12/8 14:00-15:30
報告者務必於開始前三十分鐘到達，並將報告之投影片(以Power Point製作並存放於隨身碟)，交付現場服務人員存放於該場次電腦中。
現場備有電腦(附有 USB 插槽)、單槍投影機、簡報筆及麥克風，如有其他發表設備需求，請事先與工作人員接洽。
每個人口頭報告時間為 13 分鐘(包含口頭報告 10 分鐘與提問時間 3 分鐘)。
口頭報告10分鐘內，將會再在第 8、9與第 10 分鐘時，各響鈴提示一次，共計三次，提醒報告人掌握時間；提問時間內，第12分鐘響鈴提示倒數1分鐘，第13分鐘響鈴結束討論。
優秀論文獎：
(1)由各學會敦聘專家評審進行評選。
(2)獎勵方式：於閉幕典禮頒獎。

海報論文發表規則:

報到完畢後，請找到自己的海報編號板進行張貼，海報編號請參考「投稿結果公告」。
海報張貼最慢需於發表前10分鐘完成，並在指定地點張貼完畢，會場備有張貼海報之文具供發表者使用。
請發表人於海報發表時段在張貼地點就位，以回答評審及提問者之問題，如不在場將不頒發證書及取消優秀論文獲獎資格。
各海報發表場次時段如下所示：
(1)論文海報 I 場次發表者(單數號)請於12月7日(六) 13:00~14:00就位
(2)論文海報 II 場次發表者(雙數號)請於12月8日(日) 13:00~14:00就位
優秀論文獎：
(1)由各領域的評審進行評選。
(2)獎勵方式：入選優秀論文者，大會將於閉幕典禮頒獎。

回上頁